A new study by Public Health England (PHE) shows that infant vaccination against group B meningococcal disease (MenB) has resulted in a significant decline in cases of the disease among young children in England, since the programme was introduced in September 2015.
The vaccine is offered to babies at eight and 16 weeks of age, followed by a booster on their first birthday. Infants in the first year of life have the highest incidence of MenB disease, so vaccinating at these times helps protect them when they are most at risk.
The PHE study shows that by the third year of the programme, cases of MenB disease were 62% lower in children who were eligible for at least two doses of the vaccine. Between 2015 and 2018, an estimated 277 out of an expected 446 cases were prevented because of the programme.
Source: PHE, 23 January 2020